FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy

Follicular lymphoma (FL) is a clinically and molecularly highly heterogeneous disease, yet prognostication relies predominantly on clinical tools. We recently demonstrated that integration of mutation status of 7 genes, including EZH2 and MEF2B, improves risk stratification. We mined gene expression...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Mottok, Anja, Jurinovic, Vindi, Farinha, Pedro, Rosenwald, Andreas, Leich, Ellen, Ott, German, Horn, Heike, Klapper, Wolfram, Boesl, Michael, Hiddemann, Wolfgang, Steidl, Christian, Connors, Joseph M., Sehn, Laurie H., Gascoyne, Randy D., Hoster, Eva, Weigert, Oliver, Kridel, Robert
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2018
Sujets:
Lymphoid Neoplasia
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5757687/
https://ncbi.nlm.nih.gov/pubmed/29122756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-08-799080
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires